Skip to main navigation
logo
  • About
    • Company
    • Leadership
    • Laboratory
    • Careers
  • Products
    • IMMUNO-/PRECISION ONCOLOGY
      • Immuno ID NeXT PlatformTM
      • NeXT PersonalTM
      • NeXT Liquid BiopsyTM
    • ONCOLOGY CLINICAL DIAGNOSTICS
      • NeXT Dx TestTM
    • PHARMA RESEARCH SOLUTIONS
      • Exome Sequencing
      • Transcriptome Sequencing
      • Whole Genome Sequencing
      • Targeted Cancer Panels
      • miRNA Sequencing
  • Applications
    • Biomarker Discovery
    • Personalized Therapeutics
    • Population Genomics
  • Technology
    • Our Processes
    • Unlock the power of DNA
    • Optimizing RNA
    • NeoantigenID
    • MHC binding prediction
    • ImmunogenomicsID
    • Reliable delivery
  • Resources
    • What’s New
    • Conferences
    • Library
    • Blog
    • Contact
  • Investors
    • Overview
    • Press Releases
    • Events
    • SEC Filings
    • Stock Information
    • Corporate Governance
    • Analyst Coverage
    • Investor FAQs
    • Investor Contacts
    • Email Alerts

Press Releases

Press Releases

Mar 23, 2022
Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022
Feb 24, 2022
Personalis Reports Fourth Quarter and Full Year 2021 Financial Results
Feb 23, 2022
Personalis to Present at the Cowen 42nd Annual Health Care Conference
Feb 15, 2022
Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research into Composite Biomarkers and Minimal Residual Disease Detection
Feb 10, 2022
Personalis to Announce Fourth Quarter and Full-Year Financial Results
Feb 01, 2022
Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Jan 06, 2022
Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
Displaying 11 - 17 of 17
Print Page
RSS Feeds
Email Alerts
Contact IR
Corporate Website
© 2022 Personalis Inc. All rights reserved.
logo